



103.00

RECEIVED

OCT 11 2002

FF8B
10/11/02IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

Applicant : Weers et al.) Group Art Unit 1617
Appl. No. : 09/888,311)
Filed : June 22, 2001)
For : PHOSPHOLIPID BASED) I hereby certify that this correspondence and all
POWDERS FOR) marked attachments are being deposited with the
INHALATION) United States Postal Service as first-class mail in
) an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
20231, on)
Examiner : E. Webman) 9/24/02
) (Date)
) Kathy Honnert
) Kathy Honnert
)

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated June 25, 2002 please consider the following amendments and remarks with respect to the above-captioned application.

IN THE CLAIMS

Please amend the claims as follows:

Please cancel claims 1 – 3 and 13.

*21. A method for inhalation of a dry powder drug comprising:
administering a dry powder drug composition comprising particles comprising a
phospholipid matrix and a particle size of 1-30 microns, mass median aerodynamic diameter of
less than 5 microns, and bulk density of less than 0.5 g/cm³ from a passive dry powder inhaler
wherein the emitted dose of said composition exiting from said passive dry powder inhaler after a
single inspiratory effort is at least 80% w/w and is substantially independent over an inhalation
flow rate of 20-90 l/min and device resistance of 0.04-0.20(cmH₂O)^{1/2} /L min⁻¹.*